Sigyn Therapeutics, Inc. (SIGY)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 70K 140K 210K Q2 '15: 43.7K Q3 '15: 30.2K Q4 '15: 29.2K Q4 '18: 119.4K Q1 '19: 137.8K Q2 '19: 196.3K Q3 '19: 138K Q4 '19: 143.3K Q1 '20: 102.5K Q2 '20: 38.2K Q3 '20: 9.9K Q2 '15 Q4 '15 Q1 '19 Q3 '19 Q1 '20 Q3 '20

Gross Profit TTM

0 60K 120K 180K Q4 '15: 19.3K Q4 '18: 97K Q1 '19: 115.9K Q2 '19: 157.6K Q3 '19: 103.9K Q4 '19: 107.7K Q1 '20: 75.8K Q2 '20: 28.3K Q3 '20: 6.3K Q4 '15 Q1 '19 Q3 '19 Q1 '20 Q3 '20

Operating Income TTM

-3M -2M -1M 0 1M 2M 3M Q4 '20: -916.4K Q1 '21: -1.1M Q2 '21: -1.4M Q3 '21: -1.8M Q4 '21: -2M Q1 '22: -2.2M Q2 '22: -2.3M Q3 '22: -2.3M Q4 '22: -2.1M Q1 '23: -2.1M Q2 '23: -2.1M Q3 '23: -2.2M Q4 '23: -2.5M Q1 '24: -2.6M Q2 '24: -2.6M Q3 '24: -2.8M Q4 '24: -2.5M Q1 '25: -2.4M Q2 '25: -2.3M Q3 '25: -1.9M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Net Income TTM

-4.5M -3M -1.5M 0 1.5M 3M 4.5M Q4 '20: -1.3M Q1 '21: -1.5M Q2 '21: -1.9M Q3 '21: -2.2M Q4 '21: -3M Q1 '22: -3.2M Q2 '22: -3.2M Q3 '22: -3.3M Q4 '22: -2.9M Q1 '23: -3.6M Q2 '23: -3.6M Q3 '23: -3.8M Q4 '23: -4.1M Q1 '24: -3.6M Q2 '24: -3.7M Q3 '24: -4M Q4 '24: -3.3M Q1 '25: -3.3M Q2 '25: -3.8M Q3 '25: -3.2M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Cost of Revenue TTM

0 35K 70K 105K Q4 '18: 93.3K Q1 '19: 92.9K Q2 '19: 38.7K Q3 '19: 34.1K Q4 '19: 35.7K Q1 '20: 26.7K Q2 '20: 9.8K Q3 '20: 3.6K Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20 Q2 '20 Q3 '20

Operating Cash Flow TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q4 '20: -829.8K Q1 '21: -892K Q2 '21: -1.2M Q3 '21: -1.5M Q4 '21: -1.8M Q1 '22: -2M Q2 '22: -1.9M Q3 '22: -1.9M Q4 '22: -1.8M Q1 '23: -1.9M Q2 '23: -1.9M Q3 '23: -1.7M Q4 '23: -1.4M Q1 '24: -1.1M Q2 '24: -910.3K Q3 '24: -710.1K Q4 '24: -872.4K Q1 '25: -931.3K Q2 '25: -900.9K Q3 '25: -936.4K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

Free Cash Flow TTM

-2.1M -1.4M -700K 0 700K 1.4M 2.1M Q4 '17: -400.9K Q4 '21: -1.8M Q4 '17 Q4 '21

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '19: 81.3M Q3 '19: 541.8K Q1 '20: 500K Q2 '20: 500K Q3 '20: 500K Q1 '21: 35.3M Q2 '21: 36.4M Q3 '21: 36.7M Q1 '22: 37.3M Q2 '22: 37.3M Q3 '22: 37.3M Q1 '23: 961.6K Q2 '23: 1.1M Q3 '23: 1.1M Q1 '24: 1.2M Q2 '24: 1.2M Q3 '24: 1.3M Q1 '25: 1.6M Q2 '25: 1.6M Q3 '25: 1.6M Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '20: -0.17 Q1 '21: 0.32 Q2 '21: 0.82 Q3 '21: 1.39 Q4 '21: -0.08 Q1 '22: -0.09 Q2 '22: -0.09 Q3 '22: -0.09 Q4 '22: -3.13 Q1 '23: -4.50 Q2 '23: -5.15 Q3 '23: -5.95 Q4 '23: -3.82 Q1 '24: -3.05 Q2 '24: -3.08 Q3 '24: -3.20 Q4 '24: -2.51 Q1 '25: -2.31 Q2 '25: -2.51 Q3 '25: -1.93 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.